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Abstract 
Background: The EQ-5D-3L and EQ-5D-5L are two generic health-related quality of life measures, which may be 
used in clinical and health economic research. They measure impairment in 5 aspects of health: mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. The aim of this study was to assess the performance of the 
EQ-5D-3L and EQ-5D-5L in measuring the self-reported health status of older patients with substantial multimorbidity 
and associated polypharmacy.
Methods: Between 2017 and 2019, we administered EQ-5D-3L and EQ-5D-5L to a subset of patients participating 
in the OPERAM trial at 6 months and 12 months after enrolment. The OPERAM trial is a two-arm multinational cluster 
randomised controlled trial of structured medication review assisted by a software-based decision support system 
versus usual pharmaceutical care, for older people (aged ≥ 70 years) with multimorbidity and polypharmacy. In the 
psychometric analyses, we only included participants who completed the measures in full at 6 and 12 months. We 
assessed whether responses to the measures were consistent by assessing the proportion of EQ-5D-5L responses, 
which were 2 or more levels away from that person’s EQ-5D-3L response. We also compared the measures in terms of 
informativity, and discriminant validity and responsiveness relative to the Barthel Index, which measures independ-
ence in activities of daily living.
Results: 224 patients (mean age of 77 years; 56% male) were included in the psychometric analyses. Ceiling effects 
reported with the EQ-5D-5L (22%) were lower than with the EQ-5D-3L (29%). For the mobility item, the EQ-5D-5L 
demonstrated better informativity (Shannon’s evenness index score of 0.86) than the EQ-5D-3L (Shannon’s evenness 
index score of 0.69). Both the 3L and 5L versions of EQ-5D demonstrated good performance in terms of discriminant 
validity, i.e. (out of all items of the EQ-5D-3L and EQ-5D-5L, the pain/discomfort and anxiety/depression items had the 
weakest correlation with the Barthel Index. Both the 3L and 5L versions of EQ-5D demonstrated good responsiveness 
to changes in the Barthel Index.
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Introduction
Economic evaluations in health care involve the com-
parison of the costs and the benefits of different health 
technologies [1]. Cost-effectiveness analysis is a widely 
accepted form of economic evaluation. Cost-utility 
analysis (CUA) is a specific form of cost-effectiveness 
analysis in which the benefits of health technologies 
are measured in terms of quality adjusted life years 
(QALYs) [1]. The QALY is a composite measure of both 
quantity and quality of life.
EQ-5D is a generic measure of health-related qual-
ity of life (HrQoL) which can be used in clinical and 
economic studies, and is the recommended measure 
in National Institute of Health and Care Excellence 
(NICE) guidelines for calculating QALYs in cost-utility 
analysis in England and Wales [2]. EQ-5D consists of 5 
dimensions of health i.e. mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression [3]. It also 
includes a visual analogue scale (EQ-VAS), which asks 
participants to rate their overall health on a scale from 
0 to 100. In the original of the EQ-5D (EQ-5D-3L), each 
dimension of health included 3 answer options (levels) 
to measure whether participants were experiencing no 
problems, some/moderate problems or severe/extreme 
problems [3]. However, there were concerns that the 
use of only 3-levels resulted in these levels being too 
broad so that the EQ-5D-3L measure offered only 
limited information on the degree to which respond-
ents’ health was impaired, and was also less sensitive 
to changes in respondents’ health status over time. As 
a result, a 5-level version of the EQ-5D (EQ-5D-5L) 
was subsequently developed and introduced in 2009 to 
address these concerns by providing two additional lev-
els for each dimension to enable a more nuanced pro-
file of an individual’s health status to be elicited. In the 
EQ-5D-5L, each dimension of health includes 5 levels 
to measure whether participants are experiencing no 
problems, slight problems, moderate problems, severe 
problems, or extreme/unable problems [4]. Henceforth 
in this article, we refer to the EQ-5D-3L and EQ-5D-5L 
instruments as 3L and 5L respectively.
For the purposes of economic evaluation, EQ-5D 
responses can be converted into a single index sum-
mary score based on questionnaire responses to the 
5 dimensions of health by using a valuation algorithm 
based on the social preferences of the general popula-
tion. Such evaluation algorithms are country-specific 
and are currently available for a number of countries.
The measurement properties of any HrQoL instru-
ment, such as distributional properties, consistency, 
reliability and validity, should be evaluated in order to 
assess its appropriateness for use in a specific patient 
population [5]. A measurement instrument may exhibit 
good distributional properties if the presence of ceiling 
and floor effects are low (so that responses are not con-
centrated within the highest and/or lowest levels of an 
instrument). Both 3L and 5L should demonstrate consist-
ency with each other if participants’ responses to the 5L 
matched with the corresponding levels of the 3L when 
both measures were administered at the same time point 
[6]. Reliability analysis assesses the ability of an instru-
ment to provide reproducible measurements, whereas 
validity analysis involves assessing the extent to which 
an instrument measures what it purports to measure [7]. 
Convergent (and discriminant) validity and responsive-
ness are two types of validity analysis. An instrument 
exhibits convergent validity if it is highly correlated with 
a related instrument, whereas an instrument exhibits dis-
criminant validity if it has a comparatively low correla-
tion with an unrelated instrument [5].
Responsiveness may be described as ‘longitudinal 
validity’, and assesses the degree to which an instrument 
is able to respond to a meaningful or clinically important 
external change over time [5, 8]. Given the most common 
function of the EQ-5D is to detect changes in HrQoL 
over time in clinical trials, it is particularly important to 
evaluate the responsiveness of EQ-5D. An anchor-based 
analysis may be performed to assess responsiveness. The 
objective of an anchor-based analysis is to assess whether 
scores on the measure of interest (i.e. 3L or 5L) change in 
the expected direction when compared with changes in 
the scores of a related construct or measure (the ‘anchor’ 
measure) [9, 10]. For an anchor-based responsiveness 
analysis to be undertaken, it is necessary that the anchor 
measure is responsive in the study population.
We are aware of two previous studies which have com-
pared the 3L and 5L versions of EQ-5D for people of any 
age with multimorbidity (defined in these studies as ≥ 2 
chronic conditions) [11, 12]. Our study is the first we 
are aware of, to examine the responsiveness of the 3L or 
5L in a population with substantial multimorbidity (our 
sample presented with a mean of 11.5 chronic conditions 
upon entry into our study) and polypharmacy (defined 
for this study, as 5 or more different regular drugs for 
more than 30  days). The definition of multimorbidity 
used in this study was based on the inclusion criteria for 
Conclusion: Both EQ-5D-3L and EQ-5D-5L demonstrated validity and responsiveness when administered to older 
adults with substantial multimorbidity and polypharmacy who were able to complete the measures.
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the underlying clinical trial that provided the data basis 
for the present study (presence of ≥ 3 concurrent chronic 
conditions), and is stricter than the definition of multi-
morbidity which is typically used in the clinical field 
(presence of ≥ 2 concurrent chronic conditions) [13, 14]. 
Studying the measurement properties of the 3L and 5L 
in this population is of significant interest, because this 
population is increasing in prevalence over time [15]. 
Our study is also the first head-to-head study we are 
aware of (i.e. the same individual completing both the 
3L and 5L) that has been undertaken for this population. 
In terms of studies comparing the measurement proper-
ties of 3L and 5L versions of EQ-5D, many studies have 
been carried out across other populations [16]. Most 
of these studies showed that the 5L is highly consistent 
with 3L responses, as well as offering a better level of per-
formance in terms of reduced ceiling effects and better 
informativity compared to the 3L [16–18]. Ceiling effects 
occur when a high proportion of subjects have maximum 
scores on the measurement of interest. A smaller num-
ber of studies, which have applied modern test theory 
through Rasch analysis, have also indicated improved 
performance of the 5L compared to the 3L in terms of 
demonstrating greater sensitivity [19, 20]. Furthermore, 
we are aware of only six studies comparing the respon-
siveness of the 5L and 3L. Of these, three studies found 
that the 5L was more responsive than the 3L [21–23], two 
found that the measures exhibited similar responsiveness 
[24, 25], and one study of 112 stroke patients indicated 
that the 3L was more responsive than the 5L [26].
The main objectives of this study were to:
a Assess discriminant validity, informativity and 
responsiveness of the 3L and 5L versions of EQ-5D in 
an older adult population with substantial multimor-
bidity, and polypharmacy.
b Assess consistency of the 3L and 5L, in an older adult 
population with substantial multimorbidity, and 
polypharmacy. Consistency involves assessing the 
extent to which responses based on 3L correspond to 
those based on 5L.
Methods
Data collection
The OPERAM clinical trial is a two-arm, cluster-
randomised controlled trial of a structured medica-
tion review assisted by a software-based decision 
support system versus usual care, funded by the Euro-
pean Union Horizon 2020 programme (trial identifier: 
NCT02986425) [14]. The trial was conducted in four 
centres in Belgium, Ireland, Netherlands, and Switzer-
land with a follow-up period of 12  months. The trial 
participants were 2,008 people aged 70  years or above 
with both multimorbidity (experiencing 3 or more 
chronic conditions concurrently) and polypharmacy 
(5 or more different regular drugs) [14]. The trial inter-
vention was based on the so-called ‘Systematic Tool to 
Reduce Inappropriate Prescribing’ (STRIP) assistant, 
which is deployed using a clinical decision support sys-
tem [27]. STRIP is a structured method for performing 
customised medication reviews and to detect potentially 
inappropriate prescribing [14], based on STOPP/START 
version 2 criteria for potentially inappropriate medi-
cations (STOPP) and potential prescribing omissions 
(START) [28]. Baseline characteristics of the OPERAM 
trial participants included a mean age of 80  years, 55% 
being male, 24% being university educated, and present-
ing with a mean of 11.0 comorbidities at baseline. The 
chronic comorbid conditions most commonly reported 
by OPERAM trial participants at baseline were hyper-
tension (n = 1309; 65%), hypercholesterolemia (n = 725; 
36%) and atrial fibrillation (n = 724; 36%). The OPERAM 
trial had broad eligibility criteria to improve representa-
tiveness for the population of interest, and external 
validity.
During the 6  month and 12  month participant tel-
ephone interviews, which took place between 2017 and 
2019, all trial participants were asked to verbally com-
plete questionnaires read out to them by the trial primary 
researcher, to elicit a range of trial outcomes (including 
the Barthel Index, EQ-VAS and EQ-5D-5L). The EQ-
5D-5L was included in the OPERAM trial as part of a 
pre-planned, within-trial health economic analysis, but 
also to assess HRQoL clinically [14] (primarily by using 
the EQ-VAS). In addition, after initial trial recruitment 
had been completed, the 3L questionnaire was adminis-
tered in the same way to a subset of participants of the 
OPERAM trial at the 6 month and 12 month follow-up 
time points. We chose these time points to collect EQ-5D 
data for assessment of responsiveness, as we judged that a 
6 month interval was sufficient time for clinically impor-
tant changes in patient’s health to occur. We did not use 
a longer time period, as it would have exacerbated the 
generation of missing data due to the substantial mortal-
ity rate in the target population. Based on the standard 
operating procedure for the administration of trial ques-
tionnaires, the 3L was administered at the end of the tel-
ephone interview. For patients with potential difficulty in 
concentrating, the 5L was the first questionnaire admin-
istered, followed in sequence by (1) the Morisky Medica-
tion Adherence Scale (MMAS-8), (2) the Barthel Index 
and (3) Beliefs about Medicines Questionnaire (BMQ).
In the course of the 6  month follow-up interviews, 
patients were consecutively added to the present study 
until a maximum of 75 participants was reached for each 
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country [implying a planned maximum of 300 partici-
pants in total; 300 being comparable to the sample size 
of other responsiveness studies comparing 3L and 5L 
[16]]. In this study nested within a multinational clinical 
trial, we used the combined sample across all countries 
to ensure sufficient statistical power. However, for the 
responsiveness analyses, we also carried out subgroup 
analyses at the country level to check for potential differ-
ences in the responsiveness of the instruments between 
countries. Questionnaires were completed by patients or 
proxies on behalf of the patient, usually a family mem-
ber or other responsible individual [i.e. nursing home 
employee (if applicable) or the patient’s GP [14]] if the 
patient presented with cognitive impairment or was oth-
erwise unable to respond. However, our present analysis 
was restricted to participants who self-completed the 
EQ-5D measures at 6 and 12  months. It was consid-
ered necessary to remove participants for whom a proxy 
EQ-5D report was obtained, as they were shown to have 
a markedly different health profile compared to partici-
pants who self-completed all EQ-5Ds, reflected by them 
having statistically significant lower 6  month Barthel 
Index score (i.e. greater impairments in activities of daily 
living; p < 0.001). Another reason for removing proxy 
EQ-5D responses was that these can be divergent from 
self-completed EQ-5D responses [29]. The inclusion of 
the proxy responses might have led to a situation where 
observed differences between 3 and 5L could partially be 
driven by the proxy responses, with no sufficient possibil-
ity to distinguish this. Therefore, we regarded it as more 
appropriate to focus on the responses directly provided 
by patients. Ethical approval for the study was obtained 
at the four OPERAM clinical sites.
Calculation of EQ‑5D scores
To be consistent and because no equivalent value set 
exists for Switzerland, we used German EQ-5D value 
sets for all analyses. The German time trade-off value set 
was used to calculate 3L scores (utilities) [30], and the 
German cross-walk algorithm was used to calculate 5L 
scores [31]. The German crosswalk algorithm maps 5L 
responses onto the German 3L value set to calculate 5L 
scores.
Statistical analysis
All psychometric analyses were restricted to participants 
who self-completed all items of the 3L and 5L instru-
ments at 6 months and 12 months.
Descriptive statistics
Descriptive statistics were calculated for the study sam-
ple, including participant characteristics and the dis-
tribution of participants across all of the levels and 
dimensions of the 3L and 5L at baseline (6  month 
responses) and follow-up (12 month responses) [26]. Vol-
ume and patterns of missing data for the 3L and the 5L 
were assessed. We also calculated correlation coefficients 
between the 3L and 5L index scores, between the 3L and 
VAS, and between the 5L and VAS. A very high correla-
tion between the 3L and 5L index scores might indicate 
the instruments produce similar results and imply that 
they could be used interchangeably [32].
Consistency and redistribution properties
The consistency of the EQ-5D at 6 months (i.e. first meas-
urement time point) was evaluated by cross-tabulating 
within-participant 3L and 5L responses. An inconsistent 
response was defined as a 5L response that was two or 
more levels away from the corresponding 3L response 
[6]. For example, an inconsistent response would be 
established for a participant who reported level 1 (no 
problems) using 3L but reported level 3 (some problems) 
or worse for the same dimension using 5L. An excep-
tion to this rule was made for the mobility item. Here, 
we considered responses from participants who reported 
with the 3L some problems in walking about, and also 
reported with the 5L being unable to walk about, to not 
be inconsistent. This is because the 3L mobility item is 
categorised into a person having “no problems in walk-
ing about”, “some problems in walking about” and being 
“confined to bed”. Patients who report being unable to 
walk about with the 5L, may not necessarily be confined 
to bed and may therefore instead logically report having 
“some problems in walking about” with the 3L.
The proportions of inconsistent responses for each of 
the dimensions were computed. For consistent responses, 
the redistribution properties of the 5L were also assessed 
in the cross-tabulation. For example, we were able to 
assess the redistribution of participants who reported 
‘some problems’ for a 3L dimension, across the ‘some 
problems’, ‘moderate problems’ and ‘severe problems’ lev-
els of the corresponding 5L dimension.
Ceiling effects
The proportion of participants who reported ‘no prob-
lems’ for each dimension of the 3L and the 5L was 
assessed. We also examined the proportion of partici-
pants who reported no problems for all dimensions of 3L 
and 5L (i.e. index scores of 1). McNemar’s test was used 
to test whether there were statistically significant differ-
ences in ceiling effects between the measures for each 
dimension [33]. A previous study of the general German 
population found that approximately 39% of respond-
ents aged 70–79 years and 7.6% of respondents aged 80+ 
years reported ‘no problems’ for all 5 items of the EQ-
5D-5L [34].
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Discriminant validity
The discriminant validity of the EQ-5D-3L and 5L was 
assessed by computing Spearman’s rho between each 
of the EQ-5D items, and the Barthel Index at 6 months 
[33]. The Barthel Index is a measure of individual perfor-
mance in activities of daily living (ADLs) widely used in 
the field of rehabilitation, consisting of 10 items. Barthel 
Index scores range from 0 (indicating ‘total’ dependency 
in ADLs) to 100 (indicating no dependency in ADLs) 
[35]. Spearman’s rho effect sizes of between 0.20 and 0.35 
were considered weak, between 0.35 and 0.50 moderate 
and > 0.50 strong [33]. We assessed discriminant valid-
ity for the 3L and the 5L by testing the hypothesis that 
Spearman’s rho for the EQ-5D anxiety/depression or 
pain/discomfort items with the Barthel Index would be 
lower than for the other EQ-5D items. This is because the 
other EQ-5D items (mobility, self-care, usual activities) 
measure functioning, thereby being expected to corre-
late better with the Barthel Index which measures ADL-
related functioning [36].
Responsiveness
The responsiveness of the EQ-5D-3L and 5L measures to 
changes in the Barthel Index and the EQ-VAS over time 
(i.e. between 6 and 12 months) was assessed by using an 
anchor-based analysis [8]. The Barthel Index and EQ-VAS 
were also secondary outcome measures in the OPERAM 
trial [14], due to their perceived responsiveness in the 
OPERAM population. The EQ-VAS is a visual analogue 
scale measure of a person’s self-assessed health with sta-
tus ranging from 0 to 100 [37]. The ‘anchor’ measures 
(Barthel Index and EQ-VAS) were each sub-divided into 
three categories to reflect whether (1) the participant’s 
score for the anchor measure improved clinically, (2) 
did not change in a clinically important way, or (3) clini-
cally worsened between 6 and 12 months. The threshold 
for a clinically important change was determined using a 
literature-based minimal clinically important difference 
(MCID) estimate of 8 points for the EQ-VAS [37], and 
any change in the total score of the Barthel Index can be 
considered clinically important [38]. Standardised effect 
sizes (Cohen’s D) were calculated for changes in EQ-5D 
scores between 6 and 12 months. Cohen’s D effect sizes 
of between 0.2 and 0.5 were considered small, 0.5 and 0.8 
moderate and > 0.8 large [39]. A high degree of respon-
siveness of the EQ-5D-3L/5L measures would be indi-
cated through their demonstrated ability to detect change 
in the anchor measures, i.e. positive effect sizes (moder-
ate or large) for the EQ-5D when there is an improvement 
in the anchor measure and negative effect sizes when 
there is a worsening in the anchor measure. In our study, 
both the EQ-5D-3L and EQ-5D-5L were administered in 
full, including their VAS parts that are introduced slightly 
differently. We assessed responsiveness of the EQ-5D-3L 
to change in the 3L-VAS measure, and responsiveness of 
the EQ-5D-5L to change in the 5L-VAS measure, as we 
observed differences between 3L-VAS responses and 
5L-VAS responses elicited at the 6 month time point, in 
15 out of the 224 participants in our sample (although we 
observed no differences between 3L-VAS responses and 
5L-VAS responses at the 6 month time point in 209 out 
of the 224 participants, suggesting that broadly, the VAS 
can still be considered a common anchor measure for our 
analysis). The 3L-VAS and the 5L-VAS measures are for 
all essential purposes, identical measures.
Informativity
Informativity of the EQ-5D-3L and the 5L measures 
were assessed at 6 months using the Shannon index (H′) 
and the Shannon evenness index (J′) [40]. H′ was calcu-
lated for each dimension of the 5L using the formula: 
H′ = − (proportion_none*log2(proportion_none) + pro-
portion_some*log2(proportion_some) + proportion_
moderate*log2(proportion_moderate) + proportion_
severe*log2(proportion_severe) + proportion_extreme/
unable*log2(proportion_extreme/unable), and similarly 
calculated for the 3L dimensions [21]. Higher H′ values 
indicate that responses to the dimension are more evenly 
spread across the different categories of the dimension, 
and consequently suggest greater informativity. The for-
mula for the Shannon evenness index is: J′ = H′/H′max. 
The value of H’max for the 3L is log2(3) = 1.58 and for 
the 5L is log2(5) = 2.32. Unlike H′ values, J′ values lie on 
a common 0 to 1 scale allowing for direct comparison of 
results from the 3L with the 5L.
Results
Descriptive statistics
At the 6  months follow-up in the OPERAM study, 256 
(83%) of patients reported the EQ-5D measures them-
selves, 45 (15%) had the EQ-5D measures reported by 
proxy by their next of kin, and 8 (2%) had the EQ-5D 
measures reported by proxy by some other individual 
(unspecified). Of the 256 participants, 224 participants 
also self-reported EQ-5D measures at 12  months, and 
with full completion of all 3L and 5L items at 6 and 
12  months. This sample of 224 participants was used 
for all analyses and included participants who reported 
inconsistent responses. Age, gender, education level and 
comorbidity characteristics of the sample analysed for 
this study, were broadly similar to the characteristics of 
the overall OPERAM trial population (described in the 
methods section).
Summary statistics are provided in Table  1, showing 
that 56% of participants were male, 28% were university 
educated, the highest level of education was completed 
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high school for 46% of participants, 26% of participants 
did not complete high school and 5% had spent some 
time in the 6  months before the trial started living in a 
nursing home. The average participant was experiencing 
a median of 10 coexistent chronic conditions upon enter-
ing the OPERAM trial. A small index score reduction of 
0.01 (rounded) was observed between 6 and 12 months 
for both the 3L and 5L.
In this sample at 6 months, 41 unique health states were 
represented using the EQ-5D-3L, and 99 states using the 
EQ-5D-5L. Spearman’s rho at 6  months between the 
3L and 5L index scores was 0.88 (95% CI: 0.84 to 0.90), 
between the 3L index scores and 3L-VAS was 0.41 (95% 
CI: 0.30 to 0.52), and between the 5L index score and 
5L-VAS was 0.44 (95% CI: 0.32 to 0.54).
Missing data was similar between both instruments 
(see footnotes of Appendix Tables 7 and 8).
With both the 3L and 5L, it was observed that there 
was a small reduction between the 6 and 12 month time 
points in the rate of participants reporting "no prob-
lems" in their ability to undertake usual activities [from 
73 to 68% with the 3L (Appendix Table  7), and from 
64 to 61% with the 5L (Appendix Table  8)]. There were 
no statistically significant changes at the 5% level in 
responses between 6 and 12  months, for any of the 3L 
and 5L dimensions (Appendix Tables 7 and 8). Whilst the 
pattern of change as indicated by 3L and 5L between the 
two time points is broadly similar, there were important 
differences. Notably, it was observed that for mobility 
and anxiety/depression, the direction of change was dif-
ferent between 3 and 5L (positive for 3L and negative for 
5L for both items; see Appendix Table 9).
Consistency
We assessed presence of inconsistent responses between 
3 and 5L, i.e. 5L responses that differed by ≥ 2 levels with 
the same person’s 3L response (highlighted in Appendix 
Table  10). There were 28 (3%) inconsistent responses 
between the 3L and 5L reported across items (7 (3%) 
inconsistent responses for the mobility item, 4 (2%) for 
the self-care item, 7 (3%) for the usual activities item, 4 
(2%) for the pain/discomfort item and 4 (2%) for the anxi-
ety/depression item). The 28 inconsistent responses were 
elicited from 26 participants in total.
Ceiling effects
A high presence of ceiling effect was observed for the 
self-care item for both instruments (84% of participants 
reported "no problems" for self-care with the EQ-5D-3L 
and 83% with the EQ-5D-5L). There was a substantially 
higher degree of ceiling effect with the EQ-5D-3L index 
score (29%) than with the EQ-5D-5L index score (22%), 
Table 1 Summary statistics (n = 224)
SD standard deviation
a At OPERAM trial baseline
Variable n Mean SD
Age (years) 224 77.5 5.35
Number of coexistent chronic  conditionsa 224 11.5 (median = 10) 6.01
Number of  medicationsa 224 9.3 3.34
Barthel Index 6 months 224 95.2 8.81
EQ-5D-3L index score 6 months 224 0.83 0.21
EQ-5D-3L index score 12 months 224 0.82 0.22
EQ-5D-5L index score 6 months 224 0.81 0.19
EQ-5D-5L index score 12 months 224 0.80 0.21
EQ-VAS score 6 months 224 69.9 15.71
Variable n (%)
Gender (male) 126 (56.2%)
Highest level of education—university 62 (27.6%)
Highest level of education—high school 102 (45.5%)
Highest level of education—less than high school 59 (26.3%)
Highest level of education—not applicable/reported 1 (0.4%)
Spent some time in the 6 months before trial in nursing home 10 (4.4%)
Country of residence—Switzerland 55 (24.5%)
Country of residence—Ireland 48 (21.4%)
Country of residence—Belgium 58 (25.8%)
Country of residence—Netherlands 63 (28.1%)
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which was a statistically significant difference (p < 0.001) 
(Table 2).
For comparison, 4 participants (2%) reported a VAS 
score of 100 at 6 months (indicating they have the ‘best 
health they can imagine’). All 4 of these participants also 
reported full health with both the 3L and 5L at 6 months. 
81 participants (36%) reported a Barthel Index score of 
100 at 6 months (indicating they have no dependency in 
ADLs). Of these, 58 participants reported full health with 
the 3L, and 44 participants reported full health with the 
5L at 6 months.
Validity
For discriminant validity, we assessed the correlation 
between the EQ-5D items and Barthel Index (Table  3). 
There were no statistically significant differences at the 
5% level between the 3L and 5L items, in terms of how 
correlated they were with the Barthel Index (absence of 
statistically significant differences was demonstrated 
from all 95% confidence intervals for the 3L items over-
lapping with the 95% confidence intervals for the cor-
responding 5L items). Although the difference was not 
statistically significant, it is observed that the negative 
correlation between the mobility domain and the Barthel 
index was larger in magnitude for the 5L. We found that 
out of all items of the 3L and 5L, the pain/discomfort and 
anxiety/depression items had the weakest correlation 
with the Barthel Index.
Responsiveness
142 participants (64%) reported no change in their total 
Barthel Index score between 6 and 12 months. Respon-
siveness analysis demonstrated both EQ-5D measures 
were responsive to changes in the Barthel Index from 6 
to 12  months (Table  4). Evidence of responsiveness of 
both measures to changes in the Barthel Index, was dem-
onstrated both in the overall sample (Table  4), as well 
as in each of the country-specific subgroups (Appen-
dix Tables  11, 12, 13, 14). Furthermore, compared to 
each other, both 3L and 5L measures were similar in 
their responsiveness to changes in the Barthel Index. 
For both the 3L and 5L, Cohen’s D effect sizes changed 
from a moderate positive effect when the Barthel Index 
improved to a small negative effect when the Barthel 
Index worsened.
Both the 3L and 5L demonstrated some degree 
of responsiveness to changes in the VAS from 6 to 
12  months (Table  5). Compared with each other, both 
3L and 5L measures demonstrated similar responsive-
ness to changes in the VAS. There was a small positive 
improvement in 3L and 5L scores as the patient’s VAS 
scores improved. This improvement in the overall sam-
ple appeared to be driven by improvements in 3L and 
5L scores in the Netherlands and Ireland (Appendix 
Tables 17, 18). However, there was no statistically signifi-
cant change in in 3L and 5L scores for the patients whose 
VAS scores worsened from 6 to 12 months.
Informativity
Shannon’s evenness indices indicated that the 3L and 
5L were informative for mobility, usual activities and 
pain/discomfort dimensions, although less informa-
tive for self-care and anxiety/depression dimensions 
(Table  6). The EQ-5D-3L was slightly more informative 
Table 2 Percentage of  patients with  a  ceiling effect 
for  each dimension of  the  completed EQ-5D-3L 
and  EQ-5D-5L instruments and  for  the overall measures 
at 6 months (n = 224)
*Probability values presented in italic indicate significant decreases in ceiling 
effects from using the EQ-5D-5L measure compared with the EQ-5D-3L measure 
(calculated using McNemar’s test)
EQ‑5D dimension EQ‑5D‑3L (%) EQ‑5D‑5L (%) p values*
Mobility 50.8 39.2  < 0.001
Self-care 84.3 83.4 0.48
Usual activities 72.7 63.8 < 0.001
Pain/discomfort 50.4 44.6 0.002
Anxiety/depression 83.4 79.0 0.003
Index score 29.4 22.3 < 0.001
Table 3 Correlation coefficients of dimensions of the EQ-5D measures with the Barthel Index (n = 224)
CI confidence interval
a Spearman’s rho effect sizes of between 0.20 and 0.35 are considered weak, between 0.35 and 0.50 moderate, > 0.50 strong
b Higher EQ-5D item score indicates worse health problems; higher EQ-5D index score indicates better health
Dimension RS between 3L and Barthel 
 Indexa,b
95% CI RS between 5L and Barthel 
 Indexa,b
95% CI
Mobility − 0.37 − 0.48 to − 0.25 − 0.42 − 0.52 to − 0.30
Selfcare − 0.57 − 0.65 to − 0.48 − 0.58 − 0.66 to − 0.48
Usual activities − 0.45 − 0.55 to − 0.34 − 0.42 − 0.52 to − 0.31
Pain/discomfort − 0.15 − 0.27 to − 0.02 − 0.16 − 0.28 to − 0.03
Anxiety/depression − 0.14 − 0.27 to − 0.01 − 0.13 − 0.26 to − 0.003
Page 8 of 17Bhadhuri et al. Health Qual Life Outcomes          (2020) 18:317 
with respect to self-care (EQ-5D-3L J′ = 0.48; EQ-5D-5L 
J′ = 0.42), and the EQ-5D-5L was substantially more 
informative with respect to mobility (EQ-5D-3L J′ = 0.69; 
EQ-5D-5L J′ = 0.86).
Discussion
In this study, we investigated the measurement proper-
ties of the EQ-5D-3L and EQ-5D-5L in older adults with 
substantial multimorbidity. From our analyses, we found 
a low proportion of inconsistent responses between the 
EQ-5D-3L and EQ-5D-5L, which was also found in the 
majority of previous studies comparing the 3L and 5L 
[16]. This indicates 5L responses distribute logically with 
the 3L responses. The EQ-5D-3L represented 41 unique 
health states out of a possible 243 states (17%), and the 
EQ-5D-5L represented 99 unique health states out of a 
possible 3,125 states (3%). This shows that more of the 
descriptive space of the 3L is used. Both the EQ-5D-3L 
and EQ-5D-5L exhibited discriminant validity with the 
Barthel Index; which was also found in a previous study 
[36]. Missing data occurrence at 12  months was also 
similar between the two measures. Almost all miss-
ing data resulted from participants not being available 
at 12  months to provide necessary information for sec-
ondary outcome measures of the main OPERAM trial 
through telephone interview (e.g. due to trial drop-out), 
and should not be considered reflective of the perfor-
mance of the EQ-5D measures themselves.
Table 4 Assessment of  responsiveness of  the  EQ-5D-3L and  the  EQ-5D-5L measures to  changes in  the  Barthel Index 
(n = 224)
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
*p < 0.05; **p < 0.01; ***p < 0.001
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months 
(mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)a
n % reporting 3L 
score increase
Barthel Index
 Improved 0.68 0.83 0.16 (0.07 to 0.25) 0.66** 31 55
 No change 0.89 0.87 − 0.02 (− 0.05 to 0.02) − 0.09 142 25
 Worsened 0.74 0.66 − 0.08 (− 0.16 to 0.00) − 0.30* 50 28
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months 
(mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 5L 
score increase
Barthel Index
 Improved 0.68 0.81 0.13 (0.07 to 0.20) 0.66*** 31 59
 No change 0.87 0.86 − 0.01 (− 0.04 to 0.02) − 0.05 142 32
 Worsened 0.73 0.65 − 0.09 (− 0.14 to − 0.03) − 0.36** 50 32
Table 5 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS (n = 224)
MCID minimal clinically important change
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
*p < 0.05; **p < 0.01
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 3L 
score increase
3L-VAS
 Improved 0.80 0.88 0.08 (0.02 to 0.14) 0.40* 52 44
 No MCID 0.85 0.81 − 0.04 (− 0.10 to 0.01) − 0.19 101 30
 Worsened 0.81 0.79 − 0.02 (− 0.06 to 0.02) − 0.07 71 21
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
N % reporting 5L 
score increase
5L-VAS
 Improved 0.78 0.84 0.06 (0.01 to 0.10) 0.31* 55 45
 No MCID 0.83 0.81 − 0.03 (− 0.07 to 0.02) − 0.13 98 36
 Worsened 0.80 0.78 − 0.02 (− 0.06 to 0.02) − 0.11 71 28
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We observed high rates of ‘no problems’ with 3L and 
5L self-care and anxiety/depression items, which could 
suggest that the EQ-5D description of levels excludes the 
type of self-care or anxiety/depression problems encoun-
tered by the patient population studied. Alternatively, it 
may be the case that patients genuinely do not have such 
problems, or that care settings are working well to enable 
self-care.
Consistent with most other studies [16, 41, 42] includ-
ing an assessment of the subgroup of multimorbid 
patients in a study by Thompson et al. [11], in our sam-
ple we observed a reduction in ceiling effects from using 
the EQ-5D-5L (22%) compared to the EQ-5D-3L (29%). 
The EQ-5D-5L therefore appears to better capture vari-
ability in health status among those who have a high level 
of health, compared with the EQ-5D-3L. Also consist-
ent with all the studies identified in a systematic review 
by Buchholz et  al. in 2018 [16] was our finding of an 
overall improvement in informativity from using the 5L 
compared to the 3L. This was the consequence of a sub-
stantially higher Shannon evenness index score for the 
mobility item of the 5L compared with the 3L; which 
was also observed in a study of multimorbid adults by 
Thompson et al. [11]. However, informativity in our study 
was higher on the 3L than with the 5L for self-care.
We observed similar responsiveness to change over 
time for the EQ-5D-3L and EQ-5D-5L. Several studies 
evaluating responsiveness have reported an improve-
ment in responsiveness from using the EQ-5D-5L com-
pared with the EQ-5D-3L [21–23], but other studies have 
reported either no difference in responsiveness [24, 25] or 
a reduced responsiveness from using the EQ-5D-5L com-
pared with the EQ-5D-3L [26]. Given the mixed findings 
across these responsiveness studies, there is currently 
no clear evidence that using the 5L instead of the 3L to 
collect utility data for economic evaluations, will lead 
to systemically different incremental QALY estimates. 
This contrasts with the notion by Hernandez-Alava et al. 
(2018), that using the 5L instead of the 3L will lead to sys-
temically lower estimates of incremental QALYs [43]. In 
our study, both the 3L and 5L were more responsive to 
the Barthel Index than they were to the VAS. This may 
be because the VAS measures a broader underlying con-
struct of health, whereas the Barthel Index is a disability-
specific measure. Feng et  al. also previously observed a 
weak correlation between EQ-VAS change scores with 5L 
change scores [44].
This is the first study to investigate measurement prop-
erties of the EQ-5D-3L and EQ-5D-5L in older adults 
with substantial multimorbidity, through a head-to-
head comparison. The 5L and 3L were not administered 
directly after each other, which probably reduced the 
possibility of a patient’s 3L response being directly influ-
enced by the 5L response immediately beforehand. Fur-
ther separation was not possible given the set-up of the 
OPERAM trial. We were able to carry out a robust assess-
ment of responsiveness through analysis of a sample of 
224 participants who we assessed over a 6-month follow-
up period. We assessed responsiveness within a clinical 
trial, and observed for our sub-sample, only a very small 
reduction in 3L and 5L scores between 6 and 12 months. 
The findings of our study may to an extent be relevant to 
other clinical trials during which small changes in health 
are occurring (particularly in trials with a similar popu-
lation to our own), and inform the decision of whether 
to select the 3L or 5L in such trials. A limitation of our 
study is that we only investigated responsiveness of the 
instruments to changes in the Barthel Index and the EQ-
VAS. Investigation of responsiveness of the instruments 
to other variables predicted to correlate with HRQoL in 
older multimorbid patients would have been desirable 
but these were not available. In our analyses, we assessed 
responsiveness of the EQ-5D-3L to change in the 3L-VAS 
measure, and responsiveness of the EQ-5D-5L to change 
in the 5L-VAS measure. We did this to prevent results 
from being biased in favour of one instrument over the 
other. This was due to our concern that an “order effect” 
might be induced [45], in which 5L-VAS responses were 
influenced by responding to the EQ-5D-5L directly 
beforehand and 3L-VAS responses were influenced by 
responding to the EQ-5D-3L directly beforehand.
Furthermore, as the sample size of proxy EQ-5D 
responses gathered was too small, and the participants 
from whom proxy responses were elicited had more 
Table 6 Shannon’s index (H′) and Shannon’s evenness index (J′) values for EQ-5D-3L and EQ-5D-5L measures at 6 months
Dimension 3L 5L
No. of patients H′ J′ No. of patients H′ J′
Mobility 224 1.09 0.69 224 1.99 0.86
Self-care 224 0.75 0.48 224 0.96 0.42
Usual activities 224 0.94 0.59 224 1.51 0.65
Pain/discomfort 224 1.27 0.80 224 1.85 0.80
Anxiety/depression 224 0.73 0.46 224 1.05 0.45
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physical health impairments than self-reporting partici-
pants, we removed proxy responders from our analyses. It 
was not feasible under these circumstances to investigate 
the measurement properties of proxy EQ-5D responses 
for older multimorbid adults. However, a separate analysis 
comparing the patient and proxy responses that we col-
lected is planned for a future publication. Another limita-
tion was that there may be country differences but that, 
given the sample size and the heterogeneity of the sam-
ple, these could be confirmed or assessed in detail. Larger 
studies would be required for this. Furthermore, our sam-
ple presented with a notably large number of multi-mor-
bidities (mean of 11.5; median of 10 concurrent chronic 
conditions); hence, caution in generalising our results to 
older adults with fewer comorbidities should be exercised.
Another possible limitation is that we decided to use 
the German crosswalk method to calculate 5L scores 
instead of the German 5L value set. We did this because 
using the crosswalk method instead of a national value 
set is still a recognized standard in some major guide-
lines for calculating 5L scores for economic evaluations 
[2], indicating this is currently best practice. The impli-
cations of this decision on the results from our study 
are not known.
One potential area of future research is to compare 
test–retest reliability of the EQ-5D-3L and the EQ-
5D-5L. Investigation of this property was beyond the 
scope of this study and few prior studies comparing the 
EQ-5D-3L and EQ-5D-5L have investigated this prop-
erty, which relates to how strongly correlated repeated 
EQ-5D scores are [16, 46].
Both the EQ-5D-3L and EQ-5D-5L demonstrated sat-
isfactory performance in this study, thus justifying their 
use as measures for HRQoL studies and cost-utility 
analyses of older people with multimorbidity. However, 
prominent guidelines recommend to use the EQ-5D-5L 
consistently across all diseases and populations [2], and 
the overall consensus of the literature comparing the 
measurement properties of the 3L and 5L in different 
patient populations, is that the 5L exhibits better meas-
urement properties compared to the 3L [16]. Neverthe-
less, it also needs to be considered that the 3L may be 
considered slightly less burdensome to complete than 
the 5L due to having fewer response options. Also, 
when compared to the 5L the appropriate value sets for 
the 3L are currently available more widely.
We conclude that both the EQ-5D-3L and EQ-5D-5L 
exhibit a reasonably high level of performance for 
measuring the health of older adults with substantial 
multimorbidity and associated polypharmacy and who 
display the ability to self-complete the questionnaires.
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Table 7 Descriptive statistics: reported level of problem by dimensions in EQ-5D-3L
*Non-parametric test for trend across ordered groups developed by Cuzick [47]. We used this to test for differences between 6 and 12 months in responses for each 
EQ-5D-3L item
**At 12 months, 224 participants self-reported the EQ-5D-3L in full; 19 provided no response to 3L; 13 had 3L proxy reported by next of kin
Dimension 6 months n (%) % 12 months n (%) % p value*
Mobility
 No problems 114 50.8 112 50.0 0.74
 Some problems 107 47.7 106 47.3
 Confined to bed 3 1.3 6 2.7
 ANY problem 110 49.0 112 50.0
Self-care
 No problems 189 84.3 183 81.7 0.45
 Some problems 26 11.6 31 13.8
 Unable to wash/dress 9 4.0 10 4.4
 ANY problem 35 15.6 41 18.2
Usual activities
 No problems 163 72.7 152 67.8 0.21
 Some problems 57 25.4 63 28.1
 Unable to perform 4 1.7 9 4.0
 ANY problem 61 27.1 72 32.1
Pain/discomfort
 No pain/discomfort 113 50.4 122 54.4 0.38
 Moderate pain/discomfort 97 43.3 90 40.1
 Extreme pain/discomfort 14 6.2 12 5.3
 ANY problem 111 49.5 102 45.4
Anxiety/depression
 Not anxious or depressed 187 83.4 182 81.2 0.54
 Moderately anxious/depressed 33 14.7 38 16.9
 Extremely anxious/depressed 4 1.7 4 1.7
 ANY problem 37 16.4 42 18.6
 No problem on all dimensions 66 29.4 66 29.4
Page 12 of 17Bhadhuri et al. Health Qual Life Outcomes          (2020) 18:317 
Table 8 Descriptive statistics: reported level of problem by dimensions in EQ-5D-5L
*Non-parametric test for trend across ordered groups developed by Cuzick [47]. We used this to test for differences between 6 and 12 months in responses for each 
EQ-5D-5L item
**At 12 months, 226 participants self-reported the EQ-5D-5L in full; 15 provided no response to 5L, 14 had 5L proxy reported by next of kin; 1 partially reported the 5L 
by responding only to the 5L usual activities, pain/discomfort and anxiety/depression items
Dimension 6 months n % 12 months n % p value*
Mobility
 No problems 88 39.2 90 40.1 0.87
 Slight problems 60 26.7 49 21.8
 Moderate problems 44 19.6 56 25.0
 Severe problems 27 12.0 24 10.7
 Unable to walk around 5 2.2 5 2.2
 ANY problem 136 60.5 134 59.7
Self-care
 No problems 187 83.4 177 79.0 0.21
 Slight problems 15 6.7 14 6.2
 Moderate problems 8 3.5 18 8.0
 Severe problems 7 3.1 6 2.6
 Unable to wash or dress 7 3.1 9 4.0
 ANY problem 37 16.5 47 21.0
Usual activities
 No problems 143 63.8 136 60.7 0.36
 Slight problems 35 15.6 32 14.2
 Moderate problems 34 15.1 40 17.8
 Severe problems 10 4.4 10 4.4
 Unable to do usual activities 2 0.8 6 2.6
 ANY problem 81 36.2 88 39.3
Pain/discomfort
 No pain/discomfort 100 44.6 111 49.5 0.50
 Slight pain/discomfort 46 20.5 37 16.5
 Moderate pain/discomfort 49 21.8 47 20.9
 Severe pain/discomfort 29 12.9 26 11.6
 Extreme pain/discomfort 0 0.0 3 1.3
 ANY problem 124 55.4 113 50.4
Anxiety/depression
 Not anxious or depressed 177 79.0 178 79.4 0.92
 Slightly anxious/depressed 28 12.5 26 11.6
 Moderately anxious/depressed 12 5.3 13 5.8
 Severely anxious/depressed 5 2.2 6 2.6
 Extremely anxious/depressed 2 0.8 1 0.4
 ANY problem 47 21.0 46 20.5
 No problem on all dimensions 50 22.3 49 21.9
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Table 9 “Any” problem rates reported using 3L / 5L at 6 and 12 months (%)
6 months 3L 12 months 3L Change in rate 
(3L) %
6 months 5L 12 months 5L Change 
in rate (5L) 
%
Mobility 49.1 50.0 0.9 60.7 59.8 − 0.9
Self-care 15.6 18.3 2.7 16.5 21.0 4.5
Usual activities 27.2 32.1 4.9 36.2 39.3 3.1
Pain/discomfort 49.6 45.5 − 4.0 55.4 50.4 − 4.9
Anxiety/depression 16.5 18.8 2.2 21.0 20.5 − 0.4
Table 10 Cross-tabulation of 3L and 5L responses at 6 months (n = 224)
*Bold values represent inconsistent responses. An inconsistent response was defined as an EQ-5D-5L response which was two or more levels away from the 
respondent’s EQ-5D-3L response. An exception to this rule was made for the mobility item. Here, we considered responses from participants who reported with the 3L 
some problems in walking about, and also reported with the 5L being unable to walk about, to not be inconsistent. This is because the 3L mobility item is categorised 
into a person having “no problems in walking about”, “some problems in walking about” and being “confined to bed”. People who report being unable to walk about 
with the 5L, may not necessarily be confined to bed and may therefore instead logically report having “some problems in walking about” with the 3L
3L 5L
Mobility No problems Some problems Moderate problems Severe problems Unable
No problems 85 25 4 0 0
Some problems 3 35 40 27 2
Confined to bed 0 0 0 0 3
3L 5L
Self‑care No problems Some problems Moderate problems Severe problems Unable
No problems 184 5 0 0 0
Some problems 3 10 7 6 0
Unable 0 0 1 1 7
3L 5L
Usual activities No problems Some problems Moderate problems Severe problems Unable
No problems 142 15 6 0 0
Some problems 1 20 28 8 0
Unable 0 0 0 2 2
3L 5L
Pain/discomfort No problems Some problems Moderate problems Severe problems Extreme
None 98 13 2 0 0
Moderate 2 33 47 15 0
Extreme 0 0 0 14 0
3L 5L
Anxiety/depression No problems Some problems Moderate problems Severe problems Extreme
None 176 11 0 0 0
Moderate 1 17 11 2 2
Extreme 0 0 1 3 0
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Table 11 Assessment of  responsiveness of  the  EQ-5D-3L and  the  EQ-5D-5L measures to  changes in  the  Barthel Index, 
for the subgroup in Switzerland
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
*p < 0.05
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)a
n % reporting 3L 
score increase
Barthel Index
 Improved 0.41 0.79 0.38 (0.04 to 0.71) 1.63* 4 100
 No change 0.93 0.89 − 0.03 (− 0.10 to 0.02) − 0.23 39 15
 Worsened 0.84 0.70 − 0.13 (− 0.30 to 0.02) − 0.54 12 17
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 5L 
score increase
Barthel Index
 Improved 0.40 0.73 0.32 (0.01 to 0.63) 1.49 4 100
 No change 0.91 0.90 − 0.01 (− 0.05 to 0.02) − 0.11 39 15
 Worsened 0.78 0.71 − 0.06 (− 0.20 to 0.07) − 0.28 12 33
Table 12 Assessment of  responsiveness of  the  EQ-5D-3L and  the  EQ-5D-5L measures to  changes in  the  Barthel Index, 
for the subgroup in Belgium
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)a
n % reporting 3L 
score increase
Barthel Index
 Improved 0.54 0.67 0.12 (− 0.21 to 0.45) 0.34 5 40
 No change 0.84 0.84 0.00 (− 0.04 to 0.03) 0.00 37 22
 Worsened 0.80 0.67 − 0.13 (− 0.29 to 0.03) − 0.65 15 20
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 5L 
score increase
Barthel Index
 Improved 0.63 0.64 0.01 (− 0.09 to 0.11) 0.07 5 20
 No change 0.81 0.81 0.00 (− 0.03 to 0.03) 0.00 37 38
 Worsened 0.75 0.63 − 0.11 (− 0.24 to 0.01) − 0.67 15 33
Table 13 Assessment of  responsiveness of  the  EQ-5D-3L and  the  EQ-5D-5L measures to  changes in  the  Barthel Index, 
for the subgroup in Netherlands
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)a
n % reporting 3L 
score increase
Barthel Index
 Improved 0.79 0.88 0.09 (0.00 to 0.18) 0.58 11 55
 No change 0.87 0.90 0.02 (− 0.01 to 0.07) 0.22 37 41
 Worsened 0.69 0.63 − 0.03 (− 0.13 to 0.07) − 0.10 15 40
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 5L 
score increase
Barthel Index
 Improved 0.73 0.85 0.12 (0.02 to 0.22) 0.78 11 64
 No change 0.84 0.87 0.03 (− 0.01 to 0.08) 0.21 37 43
 Worsened 0.68 0.62 − 0.06 (− 0.15 to 0.03) − 0.21 15 27
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Table 14 Assessment of  responsiveness of  the  EQ-5D-3L and  the  EQ-5D-5L measures to  changes in  the  Barthel Index, 
for the subgroup in Ireland
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months 
(mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)a
n % reporting 3L 
score increase
Barthel Index
Improved 0.71 0.87 0.15 (− 0.05 to 0.36) 0.74 11 45
No change 0.90 0.84 − 0.05 (0.18 to 0.06) − 0.25 29 24
Worsened 0.57 0.57 0.00 (− 0.29 to 0.29) 0.00 8 38
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months 
(mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 5L 
score increase
Barthel Index
 Improved 0.73 0.86 0.12 (− 0.01 to 0.26) 0.61 11 55
 No change 0.89 0.83 − 0.05 (− 0.16 to 0.05) − 0.25 29 31
 Worsened 0.69 0.59 − 0.09 (− 0.30 to 0.10) − 0.35 8 38
Table 15 Assessment of  responsiveness of  the  EQ-5D-3L and  the  EQ-5D-5L measures to  changes in  the  VAS, 
for the subgroup in Switzerland
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)a
n % reporting 3L 
score increase
3L-VAS
 Improved 0.92 0.93 0.01 (− 0.03 to 0.05) 0.15 10 30
 No change 0.87 0.81 − 0.06 (− 0.19 to 0.07) − 0.22 25 24
 Worsened 0.85 0.84 − 0.01 (− 0.08 to 0.06) − 0.06 20 15
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 5L 
score increase
5L-VAS
 Improved 0.90 0.91 0.01 (− 0.02 to 0.04) 0.14 10 30
 No change 0.83 0.81 − 0.02 (− 0.10 to 0.07) − 0.06 25 28
 Worsened 0.84 0.85 0.01 (− 0.06 to 0.08) 0.05 20 20
Table 16 Assessment of  responsiveness of  the  EQ-5D-3L and  the  EQ-5D-5L measures to  changes in  the  VAS, 
for the subgroup in Belgium
a Cohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
EQ‑5D‑3L 
at 6 months (mean)
EQ‑5D‑3L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑3L (95% CI)
Effect size 
(Cohen’s D)a
n % reporting 3L 
score increase
3L-VAS
 Improved 0.82 0.84 0.02 (− 0.05 to 0.09) 0.25 6 33
 No change 0.80 0.77 − 0.02 (− 0.11 to 0.06) − 0.12 32 25
 Worsened 0.80 0.77 − 0.02 (0.10 to 0.04) − 0.13 20 20
EQ‑5D‑5L 
at 6 months (mean)
EQ‑5D‑5L 
at 12 months (mean)
Difference between 12 
and 6 months EQ‑5D‑5L (95% CI)
Effect size 
(Cohen’s D)
n % reporting 5L 
score increase
5L-VAS
 Improved 0.70 0.70 0.00 (− 0.15 to 0.15) − 0.01 9 33
 No change 0.80 0.78 − 0.02 (− 0.07 to 0.01) − 0.17 29 41
 Worsened 0.78 0.74 − 0.03 (− 0.12 to 0.05) − 0.18 20 30
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